Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.

Chou R, Peterson K, Helfand M.

J Pain Symptom Manage. 2004 Aug;28(2):140-75. Review.

PMID:
15276195
2.

Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review.

Chou R, Clark E, Helfand M.

J Pain Symptom Manage. 2003 Nov;26(5):1026-48. Review.

PMID:
14585554
3.

Muscle relaxants for pain management in rheumatoid arthritis.

Richards BL, Whittle SL, Buchbinder R.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008922. doi: 10.1002/14651858.CD008922.pub2. Review.

PMID:
22258993
4.

Muscle relaxants--the current position in the treatment of spasticity in orthopedics.

Zygmunt M, Sapa J.

Ortop Traumatol Rehabil. 2015 Jul-Aug;17(4):423-30. doi: 10.5604/15093492.1173500.

PMID:
26468180
5.

Skeletal muscle relaxants.

See S, Ginzburg R.

Pharmacotherapy. 2008 Feb;28(2):207-13. doi: 10.1592/phco.28.2.207. Review.

PMID:
18225966
6.

Choosing a skeletal muscle relaxant.

See S, Ginzburg R.

Am Fam Physician. 2008 Aug 1;78(3):365-70. Review.

7.

Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline.

Chou R, Huffman LH; American Pain Society; American College of Physicians.

Ann Intern Med. 2007 Oct 2;147(7):505-14. Review. Erratum in: Ann Intern Med. 2008 Feb 5;148(3):247-8.

PMID:
17909211
8.

Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.

Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM.

Muscle Nerve Suppl. 1997;6:S92-120. Review.

PMID:
9826984
9.
12.

A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.

Kamen L, Henney HR 3rd, Runyan JD.

Curr Med Res Opin. 2008 Feb;24(2):425-39. doi: 10.1185/030079908X261113 . Review.

PMID:
18167175
13.

Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.

Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D.

Curr Med Res Opin. 1988;10(10):699-708.

PMID:
3286128
14.
15.

Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review.

Montané E, Vallano A, Laporte JR.

Neurology. 2004 Oct 26;63(8):1357-63. Review.

PMID:
15505149
16.

A benefit-risk assessment of baclofen in severe spinal spasticity.

Dario A, Tomei G.

Drug Saf. 2004;27(11):799-818. Review.

PMID:
15350152
17.

Treatments for spasticity and pain in multiple sclerosis: a systematic review.

Beard S, Hunn A, Wight J.

Health Technol Assess. 2003;7(40):iii, ix-x, 1-111. Review.

18.

Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.

Taricco M, Pagliacci MC, Telaro E, Adone R.

Eura Medicophys. 2006 Mar;42(1):5-15. Review.

19.

Summary of combined clinical analysis of controlled clinical trials with tizanidine.

Wallace JD.

Neurology. 1994 Nov;44(11 Suppl 9):S60-8; discussion S68-9.

PMID:
7970013
20.

Comparative profile of tizanidine in the management of spasticity.

Lataste X, Emre M, Davis C, Groves L.

Neurology. 1994 Nov;44(11 Suppl 9):S53-9.

PMID:
7970011

Supplemental Content

Support Center